LGALS8抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Jurkat cells, Hela cells, A549 cells, Primary antibody: P07332(GSR Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07332(GSR Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P07332(GSR Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of LGALS8 Antibody**

LGALS8 (galectin-8), a member of the galectin family, is a β-galactoside-binding lectin involved in diverse cellular processes, including cell adhesion, autophagy, immune regulation, and pathogen recognition. Structurally, it belongs to the tandem-repeat-type galectins, containing two carbohydrate recognition domains connected by a linker peptide. LGALS8 is expressed in various tissues and plays dual roles in cancer, acting as a tumor suppressor by promoting apoptosis or as a pro-tumorigenic factor depending on cellular context. It also participates in immune responses by modulating T-cell activity and cytokine production.

Antibodies targeting LGALS8 are essential tools for studying its expression, localization, and function. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research using LGALS8 antibodies has linked the protein to autoimmune diseases (e.g., rheumatoid arthritis), infectious diseases (e.g., viral entry inhibition), and cancer progression. Recent studies explore its interaction with cell surface receptors (e.g., integrins) and intracellular pathways (e.g., mTOR signaling). Therapeutic potential is being investigated, including blocking LGALS8 to disrupt pathogenic processes or leveraging its role in enhancing immune surveillance. Challenges remain in understanding its context-dependent mechanisms, driving demand for high-specificity antibodies in both basic and translational research.